Epitalon is a peptide that is research only, not approved for human use in the US.
Also known as Epithalon, Epithalone, AEDG peptide
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia from pineal gland research. It is promoted for longevity, telomeres and sleep, largely based on studies from a single research group.
In 1 example journal
Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. FDA removed it from the Category 2 "significant safety risk" compounding list on April 15, 2026, and FDA's advisory committee narrowly recommended adding it to the 503A bulks list in July 2026. It is not on that list yet: FDA still has to finish rulemaking, so there is no settled lawful compounding route today. The July 2026 vote was 7-4, reviewed for insomnia.
As of September 23, 2026.
Key takeaways
Preclinical only: epitalon was developed from pineal gland research in Russia. Lab and animal studies report effects on melatonin, antioxidant activity and telomerase, the enzyme that maintains the protective caps on chromosomes.
A 2025 review says it remains uncertain whether these are its real mechanisms. Most of the research comes from one group, and it has not been independently tested in rigorous human trials.
Mostly cell and animal studies plus older small human reports from the originating group; no rigorous independent human trials.
Regulators see a peptide with no human safety data and a plausible cancer concern. Aging researchers note its lifespan claims rest on animal studies.
FDA's July 2026 briefing document says there are no clinical data to support epitalon's safety in humans and no studies in patients with insomnia.
FDA briefing document for the July 2026 advisory committee: epitalonFDA reviewers said epitalon has the potential to be carcinogenic from a mechanistic standpoint, because longer telomeres are generally associated with increased cancer risk.
FDA briefing document for the July 2026 advisory committee: epitalonA 2025 cell study found epitalon lengthened telomeres in normal cells and activated a telomere-maintenance pathway in breast cancer cell lines.
Epitalon and telomere maintenance in normal and cancer cell lines (2025)The FDA advisory committee voted 7 to 4 in July 2026 to recommend adding epitalon to the compounding list for insomnia, after FDA staff recommended against it.
McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)Summaries of published guidelines, drug labels, regulators and reviews, each attributed to its source. DiscoverMedica does not employ clinicians.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.
Epitalon is not approved for human use, so DiscoverMedica links to no seller.
We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.
That has not been shown in people. Lifespan claims come from animal studies, mostly from the group that developed it.
FDA found no studies in people with insomnia. Proven options include cognitive behavioral therapy for insomnia and evaluation for sleep disorders.
Not lawfully today. Epitalon is not FDA-approved, and it is not yet on the list of ingredients pharmacies may compound from, so a licensed telehealth provider has no approved or compounded product to prescribe. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA still has to decide and complete rulemaking. We will update this page if that changes. DiscoverMedica does not link to anyone selling it.
It means the product is not made or tested for people. FDA has sent warning letters to sellers who use that label while making health claims, and says it judges a product by how it is marketed, not by the disclaimer.
Epitalon is not approved for human use in the US. Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it.
This is not a complete list of risks. Talk to a licensed clinician or pharmacist about your own situation. If you have a severe reaction, call 911. You can report side effects to the FDA through MedWatch at 1-800-FDA-1088.
Guide reviewed September 23, 2026.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.
The compounds patients most often ask us about, grouped by how much evidence stands behind them. Bring this list to your first visit.
A cheap, decades-old diabetes pill that some people ask about for weight and healthy aging.
A coenzyme every cell uses for energy; offered as IV drips and injections at longevity clinics.
An NAD+ precursor sold as a supplement. FDA confirmed in 2025 that it can be a supplement again.
A transplant drug some clinicians prescribe off-label for longevity. Human aging data are early.